Roche Laboratories Inc.

Mycophenolate Mofetil Shows Promise in Phase II Osteosarcoma Trial

• A Phase II clinical trial is evaluating mycophenolate mofetil's efficacy and safety in patients with high-grade locally advanced or metastatic osteosarcoma. • The trial aims to determine progression-free survival at 16 weeks as the primary endpoint, with secondary endpoints including overall survival and safety parameters. • Mycophenolate mofetil, an immunosuppressant, has shown anticancer activity against osteosarcoma in preclinical studies, warranting further investigation in humans. • The study involves multiple centers in Thailand and includes adolescent and adult patients who have progressed after standard chemotherapy or are not candidates for it.